Comparative effectiveness and safety of novel antidiabetic agents in the management of obstructive sleep apnea: a systematic review, meta-analysis, and network meta-analysis.

Yang YT, Hou XZ, Zhang XR, Zhang ZP, Wang SH

Respiratory medicine29 Jan 2026Cited by 2 (Europe PMC)

PMID41616874DOI10.1016/j.rmed.2026.108671PepBankPUB-41616874

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanSystematic reviewEfficacy outcome
In people with obstructive sleep apnea, pairwise meta-analysis found that tirzepatide significantly decreased the apnea-hypopnea index versus control (MD -21.89 events/h).
In plain wordsIn people with sleep apnea, tirzepatide reduced the number of breathing pauses per hour compared with control.
Peptide
Tirzepatide
Outcome
DecreaseAHI change versus control (pairwise meta-analysis)
Study
n: not reported in source
Comparator
Control
Outcome group
Sleep · Sleep
Studied dose
Dose not stated
Measurements
AHI mean difference
−21.89 events/h
tirzepatide vs control
Source sentences
Summary
Compared with the control group, SGLT-2i (MD = -7.73 events/h, 95 % CI [-9.83, -5.64]), GLP-1 RAs (MD = -5.19 events/h, 95 % CI [-6.87, -3.51]), and tirzepatide (-21.89 events/h, 95 % CI [-26.01, -17.77]) could significantly decrease AHI.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 8 RCTs and 2 non-RCTs involving 1280 OSA participants were enrolled.
Report a problemFND-4161687401
02HumanSystematic reviewEfficacy outcome
In people with obstructive sleep apnea, tirzepatide ranked highest for AHI reduction in the network meta-analysis (MD -21.85 events/h).
In plain wordsIn people with sleep apnea, tirzepatide ranked first among the drugs compared for reducing breathing pauses per hour.
Peptide
Tirzepatide
Outcome
DecreaseAHI reduction in network meta-analysis
Study
n: not reported in source
Outcome group
Sleep · Sleep
Studied dose
Dose not stated
Measurements
AHI mean difference
−21.85 events/h
network meta-analysis
Source sentences
Summary
The NMA results suggested that tirzepatide ranking highest of producing the greatest AHI reduction (MD = -21.85 events/h, 95 % CI [-27.52, -16.34]
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 8 RCTs and 2 non-RCTs involving 1280 OSA participants were enrolled.
Report a problemFND-4161687402
03HumanSystematic reviewEfficacy outcome
In people with obstructive sleep apnea, tirzepatide produced the most substantial body weight decrease in the network meta-analysis (MD -19.41 kg).
In plain wordsIn people with sleep apnea, tirzepatide ranked first among the drugs compared for reducing body weight.
Peptide
Tirzepatide
Outcome
DecreaseBody weight reduction in network meta-analysis
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
Body weight mean difference
−19.41 kg
network meta-analysis
Source sentences
Summary
along with the most substantial decreases in body weight (MD = -19.41 kg, 95 % CI [-21.00, -17.82]
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 8 RCTs and 2 non-RCTs involving 1280 OSA participants were enrolled.
Report a problemFND-4161687403
04HumanSystematic reviewEfficacy outcome
In people with obstructive sleep apnea, tirzepatide produced the most substantial systolic blood pressure decrease in the network meta-analysis (MD -5.86 mmHg).
In plain wordsIn people with sleep apnea, tirzepatide ranked first among the drugs compared for lowering systolic blood pressure.
Peptide
Tirzepatide
Outcome
DecreaseSystolic blood pressure reduction in network meta-analysis
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated
Measurements
Systolic blood pressure mean difference
−5.86 mmHg
network meta-analysis
Source sentences
Summary
(MD_SBP = -5.86 mmHg, 95 % CI [-7.97, -3.74]
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 8 RCTs and 2 non-RCTs involving 1280 OSA participants were enrolled.
Report a problemFND-4161687404
05HumanSystematic reviewEfficacy outcome
In people with obstructive sleep apnea, tirzepatide produced the most substantial diastolic blood pressure decrease in the network meta-analysis (MD -1.96 mmHg).
In plain wordsIn people with sleep apnea, tirzepatide ranked first among the drugs compared for lowering diastolic blood pressure.
Peptide
Tirzepatide
Outcome
DecreaseDiastolic blood pressure reduction in network meta-analysis
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated
Measurements
Diastolic blood pressure mean difference
−1.96 mmHg
network meta-analysis
Source sentences
Summary
MD_DBP = -1.96 mmHg, 95 % CI [-3.45, -0.46]
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 8 RCTs and 2 non-RCTs involving 1280 OSA participants were enrolled.
Report a problemFND-4161687405

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.